Aprea Therapeutics Inc

NASDAQ:APREUnited States

Aprea Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on developing and commercializing novel cancer therapeutics that reactivate mutant protein 53 (p53) tumor suppressor protein. The Company's lead product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes, or myelodysplastic syndromes (MDS), and acute myeloid leukemia (AML). The Company's APR-548 is a second generation p53 reactivator that is a unique analog of eprenetapopt and therefore a pro-drug of MQ. APR-548 exhibits high oral bioavailability in preclinical testing and is being developed in an oral dosage form. The Company has initiated a Phase I clinical trial testing APR-548 in relapsed/refractory MDS and AML. Its solid tumor program includes its clinical trial evaluating eprenetapopt with anti-PD-1 therapy in advanced solid tumors.

Contact Information

Headquarters

535 Boylston StBOSTON, MA, United States 02116-3720

Phone

609-510-4718

Fax

302-655-5049

Executives

Chairman of the Board, Chief Executive Officer

Christian Schade

President, Director

Oren Gilad

Chief Financial Officer, Senior Vice President, Secretary

Scott Coiante

Chief Operating Officer, Senior Vice President

Gregory Korbel

Senior Vice President, Chief Scientific Officer

Lars Abrahmsen